An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation

Jairo Garcia, L. Michael Kettel, Nancy A. Klein, Randall R. Odem, Alan S. Penzias, Kaylen M. Silverberg, Michael P. Steinkampf, James E. Young, Philip Young, Mary Mahony

Research output: Contribution to journalArticle

Abstract

This open-label, randomized, multicenter study, conducted at nine sites in the United States, compared the efficacy, safety, and local tolerability of a new aqueous formulation of recombinant follicle-stimulating hormone (Organon USA Inc.) with that of a freeze-dried cake formulation. A total of 126 clomiphene-resistant anovulatory women (World Health Organization [WHO] Group II) were randomized to one of two treatment groups, with 62 receiving the aqueous formulation and 64 receiving the cake formulation. One cycle of ovulation induction with recombinant follicle-stimulating hormone (rFSH) was administered subcutaneously as an aqueous or cake formulation, followed by human chorionic gonadotropin. Main outcome measures were ovulation and ongoing pregnancy rates and amount and duration of exposure to rFSH. Ovulation rates after one cycle of ovulation induction were similar for the aqueous (90%) and cake (83%) formulations. Ongoing pregnancy rates were also similar for the two groups (18% and 17%, respectively). The mean total amount of rFSH given to subjects was significantly lower (p=0.006) in the aqueous (818 IU) than in the cake group (1,200 IU). Mean duration of rFSH treatment was also significantly shorter (p=0.0003) in the aqueous group compared with the cake group (9.1 vs. 12.0 days). Local reactions were similar with both formulations, except for swelling, which was significantly less frequent in the aqueous group. Compared with the cake formulation, significantly less aqueous formulation was required for a significantly shorter duration to produce the same ongoing pregnancy rate.

Original languageEnglish (US)
Pages (from-to)147-165
Number of pages19
JournalToday's Therapeutic Trends
Volume22
Issue number3
StatePublished - 2004

Fingerprint

Human Follicle Stimulating Hormone
Anovulation
Clomiphene
Follicle Stimulating Hormone
Pregnancy Rate
Ovulation Induction
Ovulation
Women's Health
Chorionic Gonadotropin
Multicenter Studies
Outcome Assessment (Health Care)
Safety
Therapeutics

Keywords

  • Drug tolerance
  • FSH
  • Infertility
  • Ovulation induction

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation. / Garcia, Jairo; Kettel, L. Michael; Klein, Nancy A.; Odem, Randall R.; Penzias, Alan S.; Silverberg, Kaylen M.; Steinkampf, Michael P.; Young, James E.; Young, Philip; Mahony, Mary.

In: Today's Therapeutic Trends, Vol. 22, No. 3, 2004, p. 147-165.

Research output: Contribution to journalArticle

Garcia, J, Kettel, LM, Klein, NA, Odem, RR, Penzias, AS, Silverberg, KM, Steinkampf, MP, Young, JE, Young, P & Mahony, M 2004, 'An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation', Today's Therapeutic Trends, vol. 22, no. 3, pp. 147-165.
Garcia, Jairo ; Kettel, L. Michael ; Klein, Nancy A. ; Odem, Randall R. ; Penzias, Alan S. ; Silverberg, Kaylen M. ; Steinkampf, Michael P. ; Young, James E. ; Young, Philip ; Mahony, Mary. / An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation. In: Today's Therapeutic Trends. 2004 ; Vol. 22, No. 3. pp. 147-165.
@article{6b0c6bbc2c1a47998f502c6c92f69d4d,
title = "An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation",
abstract = "This open-label, randomized, multicenter study, conducted at nine sites in the United States, compared the efficacy, safety, and local tolerability of a new aqueous formulation of recombinant follicle-stimulating hormone (Organon USA Inc.) with that of a freeze-dried cake formulation. A total of 126 clomiphene-resistant anovulatory women (World Health Organization [WHO] Group II) were randomized to one of two treatment groups, with 62 receiving the aqueous formulation and 64 receiving the cake formulation. One cycle of ovulation induction with recombinant follicle-stimulating hormone (rFSH) was administered subcutaneously as an aqueous or cake formulation, followed by human chorionic gonadotropin. Main outcome measures were ovulation and ongoing pregnancy rates and amount and duration of exposure to rFSH. Ovulation rates after one cycle of ovulation induction were similar for the aqueous (90{\%}) and cake (83{\%}) formulations. Ongoing pregnancy rates were also similar for the two groups (18{\%} and 17{\%}, respectively). The mean total amount of rFSH given to subjects was significantly lower (p=0.006) in the aqueous (818 IU) than in the cake group (1,200 IU). Mean duration of rFSH treatment was also significantly shorter (p=0.0003) in the aqueous group compared with the cake group (9.1 vs. 12.0 days). Local reactions were similar with both formulations, except for swelling, which was significantly less frequent in the aqueous group. Compared with the cake formulation, significantly less aqueous formulation was required for a significantly shorter duration to produce the same ongoing pregnancy rate.",
keywords = "Drug tolerance, FSH, Infertility, Ovulation induction",
author = "Jairo Garcia and Kettel, {L. Michael} and Klein, {Nancy A.} and Odem, {Randall R.} and Penzias, {Alan S.} and Silverberg, {Kaylen M.} and Steinkampf, {Michael P.} and Young, {James E.} and Philip Young and Mary Mahony",
year = "2004",
language = "English (US)",
volume = "22",
pages = "147--165",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "3",

}

TY - JOUR

T1 - An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with chronic anovulation

AU - Garcia, Jairo

AU - Kettel, L. Michael

AU - Klein, Nancy A.

AU - Odem, Randall R.

AU - Penzias, Alan S.

AU - Silverberg, Kaylen M.

AU - Steinkampf, Michael P.

AU - Young, James E.

AU - Young, Philip

AU - Mahony, Mary

PY - 2004

Y1 - 2004

N2 - This open-label, randomized, multicenter study, conducted at nine sites in the United States, compared the efficacy, safety, and local tolerability of a new aqueous formulation of recombinant follicle-stimulating hormone (Organon USA Inc.) with that of a freeze-dried cake formulation. A total of 126 clomiphene-resistant anovulatory women (World Health Organization [WHO] Group II) were randomized to one of two treatment groups, with 62 receiving the aqueous formulation and 64 receiving the cake formulation. One cycle of ovulation induction with recombinant follicle-stimulating hormone (rFSH) was administered subcutaneously as an aqueous or cake formulation, followed by human chorionic gonadotropin. Main outcome measures were ovulation and ongoing pregnancy rates and amount and duration of exposure to rFSH. Ovulation rates after one cycle of ovulation induction were similar for the aqueous (90%) and cake (83%) formulations. Ongoing pregnancy rates were also similar for the two groups (18% and 17%, respectively). The mean total amount of rFSH given to subjects was significantly lower (p=0.006) in the aqueous (818 IU) than in the cake group (1,200 IU). Mean duration of rFSH treatment was also significantly shorter (p=0.0003) in the aqueous group compared with the cake group (9.1 vs. 12.0 days). Local reactions were similar with both formulations, except for swelling, which was significantly less frequent in the aqueous group. Compared with the cake formulation, significantly less aqueous formulation was required for a significantly shorter duration to produce the same ongoing pregnancy rate.

AB - This open-label, randomized, multicenter study, conducted at nine sites in the United States, compared the efficacy, safety, and local tolerability of a new aqueous formulation of recombinant follicle-stimulating hormone (Organon USA Inc.) with that of a freeze-dried cake formulation. A total of 126 clomiphene-resistant anovulatory women (World Health Organization [WHO] Group II) were randomized to one of two treatment groups, with 62 receiving the aqueous formulation and 64 receiving the cake formulation. One cycle of ovulation induction with recombinant follicle-stimulating hormone (rFSH) was administered subcutaneously as an aqueous or cake formulation, followed by human chorionic gonadotropin. Main outcome measures were ovulation and ongoing pregnancy rates and amount and duration of exposure to rFSH. Ovulation rates after one cycle of ovulation induction were similar for the aqueous (90%) and cake (83%) formulations. Ongoing pregnancy rates were also similar for the two groups (18% and 17%, respectively). The mean total amount of rFSH given to subjects was significantly lower (p=0.006) in the aqueous (818 IU) than in the cake group (1,200 IU). Mean duration of rFSH treatment was also significantly shorter (p=0.0003) in the aqueous group compared with the cake group (9.1 vs. 12.0 days). Local reactions were similar with both formulations, except for swelling, which was significantly less frequent in the aqueous group. Compared with the cake formulation, significantly less aqueous formulation was required for a significantly shorter duration to produce the same ongoing pregnancy rate.

KW - Drug tolerance

KW - FSH

KW - Infertility

KW - Ovulation induction

UR - http://www.scopus.com/inward/record.url?scp=5044221912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044221912&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 147

EP - 165

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 3

ER -